$ABVX
By issuing new shares, ABVX increased its fully diluted share capital from approximately 88-89 million shares to approximately 96 million shares, which means the company raised approximately 7-8 million new shares, resulting in a certain degree of equity dilution.
$SLS continues to stand out.
Historical Standard of Care has been around 8 months.
Meanwhile, SLS has patients with 4+ years from first dose and 27 months from second doseβand the follow-up is still ongoing.
That's in non-transplant CR2
$ABVX
Abivax announced that its American Depositary Shares (ADS) public offering received strong investor demand, and the company has increased the fundraising size from $600 million to $800 million (final pricing of approximately $125 per ADS).
$KORU
The company has submitted a 510(k) application to the U.S. FDA for the Freedom Infusion System for the treatment of **deferoxamine**.
If approved, this will further expand the indications and commercialization opportunities for the KORU infusion system.
$AAOI lower levels were posted weeks ago, but here they are again. Levels alone donβt give direction β just areas to watch. Right now Iβm eyeing a move down toward $142.64, then a bounce near $125ISH before any reclaim.
$BYND
Beyond Meat recently announced a new business arrangement with U.S. beverage distributor Big Geyser, issuing up to 4.1667 million warrants to the company.
$OUST is raising capital at $55 per share, which can be interpreted as near-term dilution pressure, but it also signals a deliberate balance-sheet strengthening ahead of potential demand expansion cycles.
$OPEN Added more to the position recently. Looking at Wave 3 with the next technical target sitting between $15 - $17 per share. Strong potential upside ahead.